19 stories
The peptides tag is a catch-all for stories that cut across drug classes — peptide chemistry, manufacturing, the broader research-peptide market, and the policy questions that shape access.
Recurring threads: peptide CDMO capacity (Bachem, PolyPeptide, BASF) and how it became the GLP-1 bottleneck; AI-driven peptide discovery using de novo design, protein language models, and transformer architectures; macrocyclic and bicyclic peptide chemistry as the route to undruggable targets; peptide-drug conjugates as the next ADC wave; the unregulated grey-market peptide economy and its safety implications; and venom-derived peptides moving toward clinical use.
If the story is about peptides as a class — chemistry, manufacturing, policy, the field's direction — it lives here. For specific peptides, drugs, or companies, follow the dedicated tags.
The Washington Post editorial board published a sharp critique of Health Secretary Kennedy, arguing that his insistence on rigorous evidence for vaccines while simultaneously pushing the FDA to deregulate peptides with minimal human safety data represents a dangerous double standard in public health policy.